Document:

Patent Security Agreement

 Exhibit 10.25 
 PATENT SECURITY AGREEMENT 
 PATENT SECURITY
AGREEMENT (this “Patent Security Agreement”) dated as of October 16, 2009, between SurgiVision, Inc., a Delaware corporation having its principal place of business at One Commerce Square, Suite 2550, Memphis, TN 38103 (the
“Pledgor”), and Boston Scientific Corporation, a Delaware corporation having its principal place of business at One Boston Scientific Place, Natick, Massachusetts 01760 (the “Lender”). 

WHEREAS, the Pledgor and the Lender are parties to that certain Loan Agreement dated as of the date hereof (as amended
and in effect from time to time, the “Loan Agreement”); 
 WHEREAS, it is a condition precedent
to the Lender’s making any of the Loans to the Pledgor under the Loan Agreement that the Pledgor execute and deliver to the Lender a patent security agreement in substantially the form hereof; 

WHEREAS, pursuant to the Loan Agreement, the Pledgor has granted to the Lender a security interest in the Pledgor’s
personal property and fixture assets, including without limitation the patents and patent applications listed on Schedule A attached hereto, to secure the payment of the Loans under the Loan Agreement; and 

WHEREAS, this Patent Security Agreement is supplemental to the provisions contained in the Loan Agreement; 

NOW, THEREFORE, in consideration of the promises contained herein and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 
 1.
DEFINITIONS. 
 Capitalized terms used herein and not otherwise defined herein shall have the
respective meanings provided therefor in the Loan Agreement. In addition, the following terms shall have the meanings set forth in this §1 or elsewhere in this Patent Security Agreement referred to below: 

Patent Security Agreement. This Patent Security Agreement, as amended and in effect from time to time. 

Patent Collateral. All of the Pledgor’s right, title and interest in and to all of the Patents, the Patent
License Rights, all other Patent Rights, and all additions, improvements, and accessions to, all substitutions for and replacements of, and all products and Proceeds (including insurance proceeds) of any and all of the foregoing, and all books and
records and technical information and data describing or used in connection with any and all such rights, interests, assets or property, in any event subject to the terms of any licensing agreements in favor of the Pledgor, or to which the Pledgor
is a party, pertaining to any Patents or Patent Rights, owned or used by third parties. 
 Patent License
Rights. Any and all present or future rights and interests of the Pledgor pursuant to any and all present and future licensing agreements in favor of the Pledgor, or to which the Pledgor is a party, pertaining to any Patents or Patent Rights,
owned or used by third parties in the present or future, including the right in the name of the Pledgor or the Lender to enforce, and sue and recover for, any past, present or future breach or violation of any such agreement. 

 Patent Rights, Any and all present or future rights in, to and
associated with the Patents throughout the world, whether arising under federal law, state law, common law, foreign law, or otherwise, including but not limited to the following: all such rights arising out of or associated with the Patents; the
right (but not the obligation) to register claims under any federal, state or foreign patent law or regulation; the right (but not the obligation) to sue or bring opposition or bring cancellation proceedings in the name of the Pledgor or the Lender
for any and all past, present and future infringements of or any other damages or injury to the Patents or the Patent Rights, and the rights to damages or profits due or accrued arising out of or in connection with any such past, present or future
infringement, damage or injury. 
 Patents. All patents and patent applications, whether United States or
foreign, that are owned by the Pledgor or in which the Pledgor has any right, title or interest, now or in the future, including but not limited to: 

    (a)        the patents and patent
applications listed on Schedule A hereto (as the same may be amended pursuant hereto from time to time); 
     (b)        all re-issues, continuations, divisions, continuations-in-part, renewals or extensions thereof; 

    (c)        the inventions disclosed or
claimed therein, including the right to make, use, practice and/or sell (or license or otherwise transfer or dispose of) the inventions disclosed or claimed therein; and 

    (d)        the right (but not the
obligation) to make and prosecute applications for such Patents, 
 Pending. With respect to any claim,
action, suit, proceeding or investigation of a party or a party’s interest in the Patent Collateral, that such party has been sued or initially notified with respect to such claim, action, suit, proceeding or investigation and such action,
suit, proceeding or investigation has not been dismissed, completed or terminated. 
 Proceeds. Any
consideration received from the sale, exchange, license, lease or other disposition or transfer of any right, interest, asset or properly which constitutes all or any part of the Patent Collateral, any value received as a consequence of the
ownership, possession, use or practice of any Patent Collateral, and any payment received from any insurer or other person or entity as a result of the destruction or the loss, theft or other involuntary conversion of whatever nature of any right,
interest, asset or property which constitutes all or any part of the Patent Collateral. 
 PTO. The
United States Patent and Trademark Office. 
 Notwithstanding anything to the contrary in the foregoing or on
Schedule A hereto, the terms “Patent Collateral”, “Patent Rights”, “Patent License Rights” and “Patents”, as used herein, shall include rights and interests under licensing agreements pursuant to which
Pledgor is the licensee, and the patents licensed thereunder, only to the extent that the grant of security interest in such rights and interests (as contemplated by this Patent Security Agreement) would not result in a breach of the terms of or
constitute a default under any such licensing agreement. 

  
 2 

 2. GRANT OF SECURITY INTEREST. 

To secure the payment in full of all of the Loans, the Pledgor hereby grants to the Lender a security interest in all of
the Patent Collateral. 
 3. REPRESENTATIONS, WARRANTIES AND COVENANTS. 

The Pledgor represents, warrants and covenants that: (i) Schedule A attached hereto sets forth a true and
complete list of all the Patents now owned, licensed, controlled or used by the Pledgor, except patents for technologies licensed pursuant to inbound “shrink-wrap” or other similarly publicly available commercial end-user licenses,
provided, that this representation is made to Pledgor’s knowledge with respect to any Patents for which Lender controls the prosecution; (ii) subject to the last paragraph of §1, the Pledgor has the right to enter into this Patent
Security Agreement and perform its terms; (iii) this Patent Security Agreement will create in favor of the Lender a valid and perfected first priority security interest in the Patent Collateral upon making the filings referred to in clause
(iv) of this §3; and (iv) except for the filing of financing statements with Secretary of State for the State of Delaware under the Uniform Commercial Code and the filing of this Patent Security Agreement with the PTO and except for
any filings which may be required in jurisdictions outside the United States, no authorization, approval or other action by, and no notice to or filing with, any governmental or regulatory authority, agency or office is required either (1) for
the grant by the Pledgor or the effectiveness of the security interest and assignment granted hereby or for the execution, delivery and performance of this Patent Security Agreement by the Pledgor, or (2) for the perfection of or the exercise
by the Lender of any of its rights and remedies hereunder. 
 4. NO TRANSFER OR INCONSISTENT AGREEMENTS.

 Without the Lender’s prior written consent, except to the extent expressly permitted hereunder or
pursuant to the Loan Agreement, the Pledgor will not (i) mortgage, pledge, assign, encumber, grant a security interest in, transfer, or alienate any of the Patent Collateral or (ii) enter into any agreement that is inconsistent with the
Pledgor’s obligations under this Patent Security Agreement. 
 5. AFTER-ACQUIRED PATENTS, ETC. 

5.1.  After-acquired Patents. If, before all of the Loans shall have been finally paid and
satisfied in full, the Pledgor shall obtain any right, title or interest in or to any other or new patents or patent applications, or become entitled to the benefit of any patent application or patent or any reissue, division, continuation, renewal,
extension, or continuation-in-part of any of the Patent Collateral or any improvement on any of the Patent Collateral, the provisions of this Patent Security Agreement shall automatically apply thereto and the Pledgor shall promptly (but in no event
more frequently than once every sixty (60) days) give to the Lender notice thereof in writing and execute and deliver to the Lender such documents or instruments as the Lender may reasonably request further to grant a security interest therein
to the Lender; provided, that such notice shall not be required to be delivered by Pledgor with respect to any such filings which are made by Lender. 
 5.2.  Amendment to Schedule. The Pledgor authorizes the Lender to modify this Patent Security Agreement, without the necessity of the Pledgor’s further approval or signature,
by amending Schedule A hereto to include any future or other Patents or Patent Rights under §2 or §5 hereof. 

  
 3 

 6. REMEDIES. 

If any Event of Default shall have occurred and be continuing, then upon notice by the Lender to the Pledgor: the Lender
shall have, in addition to all other rights and remedies given it by this Patent Security Agreement and the Loan Agreement, those allowed by law and the rights and remedies of a secured party under the Uniform Commercial Code as enacted in the State
of Delaware or Massachusetts, as applicable, and, without limiting the generality of the foregoing, subject to applicable law, the Lender may immediately, without demand of performance and without other notice (except as set forth next below) or
demand whatsoever to the Pledgor, all of which are hereby expressly waived, and without advertisement, sell or license at public or private sale or otherwise realize upon the whole or from time to time any part of the Patent Collateral, or any
interest which the Pledgor may have therein, and after deducting from the proceeds of sale or other disposition of the Patent Collateral all expenses (including all reasonable expenses for broker’s fees and legal services), shall apply the
residue of such proceeds toward the payment of the Loans as set forth in the Loan Agreement. Notice of any sale, license or other disposition of any of the Patent Collateral shall be given to the Pledgor at least five (5) Business Days before
the time that any intended public sale or other disposition of such Patent Collateral is to be made or after which any private sale or other disposition of such Patent Collateral may be made, which the Pledgor hereby agrees shall be reasonable
notice of such public or private sale or other disposition. At any such sale or other disposition, the Lender may, to the extent permitted under applicable law, purchase or license the whole or any part of the Patent Collateral or interests therein
sold, licensed or otherwise disposed of. 
 7. POWER OF ATTORNEY. 

If any Event of Default shall have occurred and be continuing, the Pledgor does hereby make, constitute and appoint the
Lender (and any officer or agent of the Lender as the Lender may select in its exclusive discretion) as the Pledgor’s true and lawful attorney-in-fact, with the power to endorse the Pledgor’s name on all applications, documents, papers and
instruments necessary for the Lender to use any of the Patent Collateral, to practice, make, use or sell the inventions disclosed or claimed in any of the Patent Collateral, to grant or issue any exclusive or nonexclusive license of any of the
Patent Collateral to any third person, or necessary for the Lender to assign, pledge, convey or otherwise transfer title in or dispose of the Patent Collateral or any part thereof or interest therein to any third person, and, in general, to execute
and deliver any instruments or documents and do all other acts which the Pledgor is obligated to execute and do hereunder. This power of attorney shall be irrevocable for the duration of this Patent Security Agreement. 

8. FURTHER ASSURANCES. 
 The Pledgor shall, at any time and from time to time, and at its expense, make, execute, acknowledge and deliver, and file and record as necessary or appropriate with governmental or regulatory
authorities, agencies or offices, such agreements, assignments, documents and instruments, and do such other and further acts and things (including, without limitation, obtaining consents of third parties), as the Lender may reasonably request or as
may be necessary in order to implement the provisions of this Patent Security Agreement or to assure and confirm to the Lender the grant, perfection and priority of the Lender’s security interest in any of the Patent Collateral. 

9. TERMINATION. 
 At such time as all of the Loans have been finally paid and satisfied in full, this Patent Security Agreement shall terminate and the Lender shall, promptly and in any event within five (5) business
days of request from Pledgor, execute and deliver to the Pledgor, at the expense of the Pledgor, all deeds, 

  
 4 

 
assignments and other instruments as may be necessary or proper to reassign and reconvey to and re-vest in the Pledgor the entire right, title and interest to the Patent Collateral previously
granted, assigned, transferred and conveyed to the Lender by the Pledgor pursuant to this Patent Security Agreement, as fully as if this Patent Security Agreement had not been made, subject to any disposition of all or any part thereof which may
have been made by the Lender in accordance herewith. 
 10. COURSE OF DEALING. 

No course of dealing among the Pledgor and the Lender, nor any failure to exercise, nor any delay in exercising, on the
part of the Lender, any right, power or privilege hereunder or under the Loan Agreement shall operate as a waiver thereof; nor shall any single or partial exercise of any right, power or privilege hereunder or thereunder preclude any other or
further exercise thereof or the exercise of any other right, power or privilege. 
 11. EXPENSES.

 Any and all fees, costs and expenses, of whatever kind or nature, including the reasonable
attorneys’ fees and legal expenses, incurred by the Lender in its capacity as secured party in connection with the payment or discharge of any taxes, counsel fees, maintenance fees, encumbrances or otherwise protecting, maintaining or
preserving any of the Patent Collateral, or in defending or prosecuting any actions or proceedings arising out of or related to any of the Patent Collateral, shall be borne and paid by the Pledgor. 

12. INDEMNIFICATION. 

THE PLEDGOR SHALL INDEMNIFY THE LENDER FOR ANY AND ALL COSTS, EXPENSES, DAMAGES AND CLAIMS, INCLUDING LEGAL FEES
(“LOSSES”). INCURRED BY THE LENDER IN ITS CAPACITY AS SECURED PARTY WITH RESPECT TO ANY CLAIM OR CLAIMS BROUGHT BY THIRD PARTIES REGARDING THE PLEDGOR’S OWNERSHIP OR PURPORTED OWNERSHIP OF, OR RIGHTS OR PURPORTED RIGHTS ARISING FROM,
ANY OF THE PATENT COLLATERAL OR ANY PRACTICE, USE, LICENSE OR SUBLICENSE THEREOF, OR ANY PRACTICE, MANUFACTURE, USE OR SALE OF ANY OF THE INVENTIONS DISCLOSED OR CLAIMED THEREIN, WHETHER ARISING OUT OF ANY PAST, CURRENT OR FUTURE EVENT,
CIRCUMSTANCE, ACT OR OMISSION OR OTHERWISE. 
 13. RIGHTS AND REMEDIES CUMULATIVE. 

All of the Lender’s rights and remedies with respect to Events of Default relating to the Patent Collateral, whether
established hereby or by the Loan Agreement or by any other agreements or by law, shall be cumulative and may be exercised singularly or concurrently. This Patent Security Agreement is supplemental to the Loan Agreement, and nothing contained herein
shall in any way derogate from any of the rights or remedies of the Lender contained therein. Nothing contained in this Patent Security Agreement shall be deemed to extend the time of attachment or perfection of or otherwise impair the security
interest in any of the Patent Collateral granted to the Lender under the Loan Agreement. 
 14. NOTICES.

 All notices and other communications made or required to be given pursuant to this Patent Security
Agreement shall be made as set forth in Section 10.1 of the Loan Agreement. 

  
 5 

 15. AMENDMENT AND WAIVER. 

This Patent Security Agreement is subject to modification only by a writing signed by the Lender and the Pledgor, except
as provided in §5.2. Neither party shall be deemed to have waived any right hereunder unless such waiver shall be in writing and signed by it. A waiver on any one occasion shall not be construed as a bar to or waiver of any right on any future
occasion. 
 16. GOVERNING LAW. 

THIS PATENT SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE COMMONWEALTH OF
MASSACHUSETTS. 
 17. MISCELLANEOUS. 

The headings of each section of this Patent Security Agreement are for convenience only and shall not define or limit the
provisions thereof. This Patent Security Agreement and all rights and obligations hereunder shall be binding upon the Pledgor and its successors and assigns and shall inure to the benefit of the Lender and its successors and assigns. In the event of
any irreconcilable conflict between the provisions of this Patent Security Agreement and the Loan Agreement, the provisions of the Loan Agreement shall control. If any term of this Patent Security Agreement shall be held to be invalid, illegal or
unenforceable, the validity of all other terms hereof shall in no way be affected thereby, and this Patent Security Agreement shall be construed and be enforceable as if such invalid, illegal or unenforceable term had not been included herein.

 [Reminder of Page Intentionally Left Blank] 

  
 6 

 IN WITNESS WHEREOF, this Patent Security Agreement has been executed
as of the day and year first above written. 
  

					
	 SURGIVISION, INC.

		
	 By:
	 	   /s/ K. Jenkins

		 	   Name:
	 	 K Jenkins

		 	   Title:
	 	 CEO

	
	 BOSTON SCIENTIFIC CORPORATION

	 By:
	 	   /s/ Sam Leno

		 	   Name:
	 	 SAM LENO

		 	   Title:
	 	 EVP, FINANCE & INFORMATION
 SYSTEMS & CFO

			
		 	 1st Name:
	 	 Jim Gilbert

		 	      Title:
	 	 EVP, Strategy & Business Development

 SIGNATURE PAGE TO PATENT SECURITY AGREEMENT 

 CERTIFICATE OF ACKNOWLEDGMENT 

 

					
	 STATE OF
	 	    Tennessee
	 	 )

		 		 	 ) ss

	 COUNTY OF
	 	    Shelby
	 	 )

 Before me, the undersigned, a Notary Public in and for the county
aforesaid, on this 16th day of October, 2009 personally appeared Kimble Jenkins to me known personally, and who, being by me duly sworn, deposes and says that he is the CEO of SurgiVision, Inc., and that said
instrument was signed and sealed on behalf of said corporation by authority of its Board of Directors, and said Kimble Jenkins acknowledged said instrument to be the free act and deed of said corporation 

 

							
		 		 	   /s/ Priscilla H. Horner
	  	
		 		 	 Notary Public
	  	
		 		 	 My commission expires:
	  	 MY COMMISSION EXPIRES:
 April 18, 2012

  
 2 

 Schedule A 

ISSUED AND PENDING PATENTS 
 [***] 
 [***] Indicates portions of this exhibit that have been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

 Schedule A 

ISSUED AND PENDING PATENTS 
 [***] 
 [***] Indicates portions of this exhibit that have been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

 Schedule A 

ISSUED AND PENDING PATENTS 
 [***] 
 [***] Indicates portions of this exhibit that have been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

 Schedule A 

ISSUED AND PENDING PATENTS 
 [***] 
 [***] Indicates portions of this exhibit that have been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

 Schedule A 

 
 ISSUED AND PENDING PATENTS 

[***] 
 [***]
Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

 Schedule A 

ISSUED AND PENDING PATENTS 
 [***] 
 [***] Indicates portions of this exhibit that have been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

 Schedule A 

ISSUED AND PENDING PATENTS 
 [***] 
 [***] Indicates portions of this exhibit that have been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

 Schedule A 

ISSUED AND PENDING PATENTS 
 [***] 
 [***] Indicates portions of this exhibit that have been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

 Schedule A 

ISSUED AND PENDING PATENTS 
 [***] 
 [***] Indicates portions of this exhibit that have been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.Research Agreement

 Exhibit 10.26 
 RESEARCH AGREEMENT 
 NO.
                 
 BY AND BETWEEN

 SURGIVISION, INC. 
 AND 
 THE UNIVERSITY OF UTAH 

This Research Agreement (“Agreement”) is entered into and effective as of
                                         
                   , by and between Surgi Vision, Inc, a Delaware corporation having a principal place of business at 200 N Cobb Parkway, Suite 140,
Marietta, Georgia 30062 (“Sponsor”) and the University of Utah, a body politic and corporate of the State of Utah (“University”). 
 RECITALS 
 WHEREAS, Sponsor wishes to fund research in MRI Guided EP
Ablation as outlined in this Agreement; and 
 WHEREAS, the performance of such research is consistent, compatible and
beneficial to the academic role and mission of University as an institution of higher education; and 
 WHEREAS, University is
qualified to provide such research. 
 AGREEMENT 
 NOW, THEREFORE, for and in consideration of the mutual covenants, conditions and undertakings herein set forth, the parties agree as follows: 
 1. Scope of Work. University agrees to perform certain research (“Research”) described in the Scope of Work set forth in Appendix A, which is attached hereto and incorporated herein by
this reference. 
 2. Period of Performance. The term of this Agreement shall be one-year, commencing on the effective date of this
Agreement. The Agreement shall automatically terminate one year from the effective date, unless both Sponsor and University agree in writing prior to the termination date, to extend the Agreement for a subsequent one-year renewal term subject to the
same terms and conditions stated herein. 
 3. Compensation and Payment. 

3.1 Compensation. Sponsor shall pay to University a total of $[***] USD (“Compensation”) in consideration for this
Agreement. The Compensation shall be used by the University substantially along the lines of the budget itemizing the costs of the Research, as set forth in Appendix B, which is attached hereto and incorporated herein by this reference. 

 

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 3.2 Payment. Sponsor shall pay an initial payment of $[***] of the Compensation
amount within 30 days of the effective date of this Agreement. Thereafter, monthly progress payments shall be made by Sponsor to University based upon monthly invoices submitted by University to Sponsor. The monthly invoices shall identify the
direct, facility and administrative costs. Invoices submitted to Sponsor shall be paid by Sponsor within thirty (30) days of receipt. Final payment shall include the unpaid balance of the Compensation and shall be paid upon completion of the
Research. Final payment of any remaining amount of Compensation unpaid at termination of the Agreement, if any, shall be made within 30 days of notification of completion of the Research. 
 Invoices shall be delivered to: 
 JOHN THOMAS 

200 N. COBB PARKWAY 
 MARIETTA, GA 30062 
 Compensation checks shall be payable to “The University of Utah”
and shall be sent to: 
 GARY S. GLEDHILL 
 UNIVERSITY OF UTAH 
 RESEARCH ACCOUNTING 

201 PRESIDENT’S CIRCLE, ROOM 406 
 SALT LAKE CITY UT 84112-9020 
 4. Technical Supervision. The person with primary
responsibility for supervision of the performance of the Research at the University shall be Dr. Nassir Marrouche. No other person shall replace or substitute for him in the supervisory responsibilities hereunder without the prior written
approval of Sponsor, which may be granted or withheld at Sponsor’s sole discretion, and with the consent of the University, which consent shall not be unreasonably withheld. 
 5. Reporting Requirements. University shall provide written reports to Sponsor on the progress of the performance of Research as outlined or required in the Scope of Work. A final written report
shall be furnished to Sponsor upon completion of the Research or within 60 days of the termination of the Agreement, whichever is earlier. 
 6.
Equipment. All equipment, instruments and materials purchased or used by University in connection with performance of the Research shall at all times remain under the control and ownership of University. This provision does not apply to
equipment, instruments or materials loaned to University by Sponsor, which shall remain the property of the Sponsor and shall be returned to Sponsor upon termination of this Agreement. 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 2 

 7. Publication and Confidentiality. 

7.1 Publication. In furtherance of University’s role as a public institution of higher education, it is necessary that
significant results of research activities be reasonably available for publication by the University, and Sponsor acknowledges that University may publish the results of research conducted in connection with this Agreement. 

Notwithstanding the foregoing, University agrees that it shall not publish the results of research conducted in connection with this
Agreement, without the prior written consent of Sponsor, until the expiration of six (6) months following the first to occur of either the termination of this Agreement or submission of the final written report required under Section 4
hereof. In the event University wishes to publish research results prior to the expiration of the above described six (6) month period, University shall first provide to Sponsor written notice of University’s intent to publish and a draft
of such publication. Sponsor shall have thirty (30) days after receipt of the draft publication to request in writing the removal of portions deemed by Sponsor to contain confidential or patentable material owned by Sponsor, or to request a
delay in submission of the draft for publication pending Sponsor’s application for patent protection. In either event, University shall have no obligation to delay publication of the draft for longer than six (6) months following delivery
of University’s notice to Sponsor of intent to publish. If University does not receive Sponsor’s written response to the notice of intent to publish within the thirty (30) day period, then Sponsor shall be deemed to have consented to
such publication. However, information supplied to University by Sponsor and identified by Sponsor as proprietary information shall not be included in any material published by University without prior written consent of Sponsor. 

7.2 Confidentiality. Confidentiality. Sponsor acknowledges that University is a governmental entity and thus subject to the Utah
Governmental Records Access Management Act, Section 63-2-101 et seq., Utah Code Ann. (1997 and Supp 2005 as amended) (“GRAMA”) and Section 53B-16-301 et seq., Utah Code Ann. (1994 and Supp. 2005). Pursuant to GRAMA, a sponsor of
research may submit a single claim of business confidentiality concerning confidential business records exchanged during the research project. Thereafter, no party may obtain confidential business records from the University absent a court order
requiring the University to disclose the records. 
 8. Indemnification. 

8.1 Indemnification by University. It is understood that the Institution is a governmental entity and is subject to the
Governmental Immunity Act of Utah, Section 63-30d-101 et seq., Utah Code Ann. (2004, as amended) (“Act”). It is further understood that nothing in this Agreement shall be construed as a waiver of any rights or defenses applicable to
the Institution under the Act, including without limitation, the provisions of Section 63-30d-604 regarding limitation of judgments. Subject to the provisions of the Act, University agrees to indemnify, defend and hold harmless Sponsor, its
directors, officers, agents and employees against any actions, suits, proceedings, liabilities and damages that may result from the negligent acts or omissions of University, its officers, agents or employees in connection with this Agreement up to
the limits of the Utah Governmental Immunity Act. 

  
 3 

 8.2 Indemnification by Sponsor. Sponsor shall indemnify, defend and hold harmless

 University, its directors, officers, agents and employees against any actions, suits, proceedings, liabilities and damages
that may result from the negligent acts or omissions of Sponsor, its officers, agents or employees in connection with this Agreement. Sponsor shall not be responsible for any acts by employees, students or agents of University for Research carried
out under this Agreement. 
 8.3 Indemnification by University. University shall indemnify, defend and hold harmless
Sponsor, its directors, officers, agents and employees against any actions, suits, proceedings, liabilities and damages that may result from the negligent acts or omissions of University, its officers, agents or employees in connection with this
Agreement. 
 9. Compliance With Laws. In performance of the Research, Sponsor and University shall comply with all applicable federal,
state and local laws, codes, regulations, rules and orders. 
 10. Patents and Inventions. 

10.1 Background Intellectual Property. “Background Intellectual Property” means property and the legal right therein of
either or both parties developed before or independent of this Agreement, including inventions, patent applications, patents, copyrights, trademarks, mask works, trade secrets and any information embodying proprietary data such as technical data and
computer software. This Agreement does not grant and shall not be construed as implying that either party hereto shall have the right to use Background Intellectual Property of the other in connection with this Research except as otherwise provided
hereunder. 
 10.2 Notification of Inventions. Should any invention or improvement be developed during the course of the
Research, University shall notify Sponsor of such invention or improvement within thirty (30) days of knowledge of the invention or improvement. 
 10.3 Ownership. The University shall own all right, title and interest in all inventions and improvements conceived or reduced to practice solely by University or University personnel in the
performance of the Research (hereinafter collectively “University Invention”). Sponsor shall own all right, title and interest in all inventions and improvements conceived or reduced to practice by Sponsor, Sponsor personnel and/or
consultants thereof in the performance of the Research (hereinafter collectively “Sponsor Invention”). The University and Sponsor will jointly own all right title and interest in all inventions and improvements jointly conceived or reduced
to practice by inventors at the University and at Sponsor in the performance of the Research (hereinafter collectively “Joint Invention”). Inventorship shall be determined in accordance with U.S. Patent Law. 

10.4 Grant of Non-Exclusive License. In consideration of Sponsor’s support of the Research, University hereby grants to
Sponsor an irrevocable fully paid-up, non-royalty bearing, worldwide non-exclusive license with the right to sublicense, any patent, copyright or other intellectual property right associated with any University Invention, including the right to
practice the University Invention and the right to make, have made, use, import, offer for sale and sell products and processes covered by the University invention. 

  
 4 

 10.5 Option for Exclusive License. The University also grants to Sponsor a 6-month
Exclusive Option Period to any University Invention or to University’s interest in any Joint Invention, which option shall expire six (6) months after University has provided written notice to Sponsor of any such University Invention or
Joint Invention (“Option Period”). Upon exercise of the option in writing, the parties will meet within thirty (30) days to begin negotiating the terms of the license. The parties agree to negotiate in good faith. In the event an
exclusive license is not executed within six (6) months from the exercise of the option, or the option is not exercised within the Option Period, then subject to the non-exclusive license in 10.4, University shall be free to license the
University Invention or the University’s interest in any Joint Invention to others, at the University’s sole discretion with no further obligation to the Sponsor. In the event the University shall affirmatively decide to not pursue legal
protection of and/or abandon its rights to any such invention or improvement prior to exercise of said option, University shall timely notify Sponsor of this decision and assign to Sponsor all of the University’s rights, title and interest
therein. 
 11. Relationship of Parties. In assuming and performing the obligations of this Agreement, University and Sponsor are each
acting as independent parties and neither shall be considered or represent itself as a joint venturer, partner, agent or employee of the other. Neither party shall use the name or any trademark of the other party in any advertising, sales promotion
or other publicity matter without the prior written approval of the other party. University shall be responsible for determining what activities are appropriate under the Research and shall direct those activities. Sponsor shall not direct nor
determine what activities shall be carried out to perform the Research and shall not be held responsible for any activities carried out by researchers performing the Research at the University. 

12. Termination. This Agreement may be terminated by either party at any time, by giving written notice thereof to the other party. Such
termination shall be effective thirty (30) days after receipt of such notice. Termination shall not relieve either party of any obligation or liability accrued hereunder prior to such termination, or rescind or give rise to any right to rescind
any payments made prior to the time of such termination. 
 13. Uncontrollable Forces. Neither Sponsor nor University shall be considered
to be in default of this Agreement if delays in or failure of performance shall be due to uncontrollable forces the effect of which, by the exercise of reasonable diligence, the nonperforming party could not avoid. The term “uncontrollable
forces” shall mean any event which results in the prevention or delay of performance by a party of its obligations under this Agreement and which is beyond the control of the nonperforming party. It includes, but is not limited to, fire, flood,
earthquakes, storms, lightning, epidemic, war, riot, civil disturbance, sabotage, inability to procure permits, licenses, or authorizations from any state, local, or federal agency or person for any of the supplies, materials, accesses, or services
required to be provided by either Sponsor or University under this Agreement, strikes, work slowdowns or other labor disturbances, and judicial restraint. 
 14. Miscellaneous. 
 14.1 Assignment. University shall not assign or
transfer any interest in this Agreement, nor assign any claims for money due or to become due under this Agreement, without the prior written consent of the Sponsor. Sponsor shall have the right to assign this Agreement and the rights under 10.4 and
10.5, with prior written consent of University, and such consent shall not be unreasonably withheld. 

  
 5 

 14.2 Entire Agreement. This Agreement, with its attachments, constitutes the entire
agreement between the parties regarding the subject matter hereof and supersedes any other written or oral understanding of the parties. This Agreement may not be modified except by written instrument executed by both parties. 

14.3 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties, their successors and
permitted assigns. 
 14.4 Notices. Except as provided in Section 3 hereof regarding payment of invoices, any notice
or other communication required or permitted to be given to either party hereto shall be in writing and shall be deemed to have been received and properly given and effective: (a) on the date of delivery if delivered in person to an employee of
University or Sponsor during recipient’s normal business hours; or (b) on the date of delivery to the Notice Address if delivered by courier, express mail service or first-class mail, registered or certified, return receipt requested. Such
notice shall be sent or delivered to the respective addresses given below, or to such other address as either party shall designate by written notice given to the other party (Notice Address) as follows: 

In the case of University: 
  

					
	Technical	 		 	Contractual
			
	  	 		 	  
	Name: Dr. Marrouche	 		 	Brent Brown
	Title: Principal Investigator	 		 	UNIVERSITY OF UTAH
	Address: 30 N 1900 E, Rm 4A100	 		 	OFFICE OF SPONSORED PROJECTS
	Salt Lake City, UT 84132	 		 	 75 South 2000 East
 SALT
LAKE CITY UT 84112

 In the case of Sponsor: 
  

					
	Technical	 		 	Contractual
			
	  	 		 	  
	Name: Pete Piferi	 		 	Name: Kimble Jenkins
	Title: COO	 		 	Title: CEO
	Address: 50 N Front St.	 		 	Address: 50 N Front St.
	19th floor, Memphis TN 38103	 		 	19th floor, Memphis TN 38103

 Correspondence to be sent with a courtesy copy to: 
 Julie Richardson, Esq. 
 Myers Bigel Sibley & Sajovec, P.A. 

4140 Parklake Ave. 
 Raleigh, NC 27627 (Fax:
919-854-1401) 

  
 6 

 14.5 Order of Precedence. In the event of any conflict, inconsistency or discrepancy
amount, the Agreement and any other documents listed below shall be resolved by giving precedence in the following order. 
 (a)
This Agreement including the Exhibits hereto 
 (b) Purchase Order issued by Sponsor. In the event a purchase order is issued
under this Agreement and such purchase order contains standardized terms and conditions, the terms and conditions of this Agreement shall supercede and replace all such purchase order standardized terms and conditions. 

14.6 Governing Law and Disputes. This Agreement shall be interpreted and construed in accordance with the laws of the State of
Utah, without application of any principles of choice of laws. Disputes that cannot be resolved by Sponsor and University shall be determined by a court of competent jurisdiction in the State of Utah. 

14.7 Nonwaiver. A waiver by either party of any breach of this Agreement shall not be binding upon the waiving party unless such
waiver is in writing. In the event of a written waiver, such a waiver shall not affect the waiving party’s rights with respect to any other or further breach. 
 14.8 Use of Name. Sponsor may not use the name of University in any news release or advertising or any publications directed to the general public without written approval of University.

 14.9 Attorney Fees. The prevailing Party in any action or suit to enforce the terms or conditions of this Agreement
shall be entitled to recover its costs of court and reasonable attorneys’ fees incurred in enforcing the terms or conditions of this Agreement. 

  
 7 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly
authorized representatives effective as of the day and year first written above. 
  

									
	SURGIVISION, INC	 		 	UNIVERSITY OF UTAH
	    “Sponsor”	 		 	    “University”
					
	By:	 	/s/ Kimble Jenkins	 		 	By:	 	/s/ Brent K. Brown
		 	Signature	 		 		 	Signature
	Name:	 	Kimble Jenkins	 		 	Name:	 	Brent K. Brown
	Title:	 	President	 		 	Title:	 	Director, Office of Sponsored Projects
	Date:	 	7/2/07	 		 	Date:	 	6/22/07
			
	NASSIR MARROUCHE	 		 	
	“Primary Researcher”	 		 	
					
	Signature:	 	/s/ Nassir Marrouche	 		 		 	
					
	Title:	 	 	 		 		 	
					
	Date:	 	 	 		 		 	

  
 8 

 APPENDIX A 
 RESEARCH SCOPE OF WORK 
 [Insert Scope of Work referenced in Article 1.] 

  
 9 

 [***] 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 10 

 APPENDIX B 
 RESEARCH AGREEMENT BUDGET 
 [Insert Budget referenced in Article 3.1] 

  
 12 

 [***] 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 13 

 FIRST AMENDMENT TO THE RESEARCH AGREEMENT 

BY AND BETWEEN 
 SURGIVISION, INC. 
 AND 

THE UNIVERSITY OF UTAH 
 This is a first Amendment to the Research Agreement (“Agreement”), by and between SurgiVision, Inc, a Delaware corporation having a principal place of business at 200 N Cobb Parkway, Suite 140,
Marietta, Georgia 30062 (“Sponsor”) and the University of Utah, a body politic and corporate of the State of Utah (“University”), executed by the Parties on July 2, 2007 and June 22, 2007, respectively. 

The enumerated provisions below replace the corresponding provisions in the original Agreement. All other provisions are unaffected by
this first Amendment. 
 NOW, THEREFORE, for and in consideration of the mutual covenants, conditions and undertakings set
forth, the parties agree to amend the Agreement as follows: 
 1. Scope of Work. University agrees to perform certain research
(“Research”) described in the Scope of Work set forth in Appendix A’, which is attached hereto and incorporated herein by this reference. 
 2. Period of Performance. The term of this Agreement shall be two-years, commencing on November 15, 2007, which shall be the new Effective Date of the Agreement. The Agreement shall
automatically terminate two years from the Effective Date, unless both Sponsor and University agree in writing, prior to the termination date, to extend the Agreement for a subsequent one or two-year renewal term subject to the same terms and
conditions stated herein, except that the monetary compensation may be altered if agreed to by both Sponsor and University in writing. 
 3.
Compensation and Payment. 
 3.1 Compensation. Sponsor shall pay to University a total of $[***] USD ($[***] under the
original Agreement and $[***] under this first Amendment) in year one (reduced by any prior payments made since execution of the original Agreement) and a total of $[***] in year two (“Compensation”) in consideration for this Agreement.
The Compensation shall be used by the University substantially along the lines of the budget itemizing the costs of the Research, as set forth in Appendix B’, which is attached hereto and incorporated herein by this reference. 

3.2 Payment. Sponsor shall remit quarterly progress payments to University based upon quarterly invoices submitted by University to
Sponsor. The invoices shall identify the direct, facility and administrative costs. Invoices submitted to Sponsor shall be paid each quarter by Sponsor within 30 days of receipt. Final payment shall include the unpaid balance of the Compensation and
shall be paid upon completion of the Research. Final payment of any remaining amount of Compensation unpaid at termination of the Agreement, if any, shall be made within 30 days of notification of completion of the Research. 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

  

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly
authorized representatives effective as of the day and year first written above. 
  

									
	SURGIVISION, INC	 		 	UNIVERSITY OF UTAH
	    “Sponsor”	 		 	    “University”
					
	By:	 	/s/ Kim Jenkins	 		 	By:	 	/s/ Brent K. Brown
		 	Signature	 		 		 	Signature
	Name:	 	Kim Jenkins	 		 	Name:	 	Brent K. Brown, Esq
		 	(Please print)	 		 		 	(Please print)
	Title:	 	CEO	 		 	Title:	 	Director, Office of Sponsored projects
	Date:	 	Nov 12, 2007	 		 	Date:	 	1/8/08
			
	NASSIR MARROUCHE	 		 	
	“Primary Researcher”	 		 	
					
	Signature:	 	/s/ Nassir Marrouche	 		 		 	
					
	Title:	 	 	 		 		 	
					
	Date:	 	 	 		 		 	

  
 2 

 APPENDIX A’ 
 RESEARCH SCOPE OF WORK 
 [***] 

 

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

  
 3 

 APPENDIX B’ 
 RESEARCH AGREEMENT BUDGET 
 See attached two sheets. 

  
 4 

 [***] 

 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 5 

 SECOND AMENDMENT TO THE RESEARCH AGREEMENT 

BY AND BETWEEN 
 SURGIVISION, INC. 
 AND 

THE UNIVERSITY OF UTAH 
 This is the second Amendment to the Research Agreement (as amended, the “Agreement”), by and between SurgiVision, Inc, a Delaware corporation having a principal place of business at One Commerce
Square, Suite 2550, Memphis, TN 38103 (“Sponsor”) and the University of Utah, a body politic and corporate of the State of Utah with a place of business at 75 South 2000 East, Rm. 211 RAB, Salt Lake City, UT 84112 (“University”),
executed by the Parties on July 2, 2007 and June 22, 2007, respectively. This Amendment has an effective date of April 24, 2009. 
 NOW, THEREFORE, for and in consideration of the mutual covenants, conditions and undertakings set forth, the Parties agree to amend the Agreement as follows: 

1. Section 3.1 Compensation. Sponsor shall pay to University a total of $[***] ($[***] under the original Agreement and previous Amendment)
in consideration for this Agreement. The Compensation shall be used by the University substantially along the lines of the budget itemizing the costs of the Research, as set forth in Appendix B, which is attached hereto and incorporated herein by
this reference. 
 All other terms and conditions of the Agreement shall remain in full force and effect and shall be unaffected
by this Second Amendment to the Research Agreement. 
 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed
by their duly authorized representatives effective as of the day and year first written above. 
  

									
	SURGIVISION, INC	 		 	UNIVERSITY OF UTAH
	    “Sponsor”	 		 	    “University”
					
	By:	 	/s/ Kim Jenkins	 		 	By:	 	/s/ Brent K. Brown
	Name:	 	Kim Jenkins	 		 	Name:	 	Brent K. Brown
	Title:	 	CEO	 		 	Title:	 	Director, Office of Sponsored Projects
	Date:	 	4/29/09	 		 	Date:	 	4/29/09
			
	NASSIR MARROUCHE	 		 	
	“Primary Researcher”	 		 	
					
	Signatures:	 	/s/ Nassir Marrouche	 		 		 	
	Date:	 	4/29/09	 		 		 	

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 THIRD AMENDMENT TO THE RESEARCH AGREEMENT 

BY AND BETWEEN 
 SURGIVISION, INC. 
 AND 

THE UNIVERSITY OF UTAH 
 This is the third Amendment to the Research Agreement (as amended, the “Agreement”), by and between SurgiVision, Inc., a Delaware corporation having a place of business at One Commerce Square,
Suite 2550, Memphis, TN 38103 (“Sponsor”), and the University of Utah, a body politic and corporate of the State of Utah with a place of business at 75 South 2000 East, Rm. 211, RAB, Salt Lake City, UT 84112 (“University”),
executed by the Parties on July 2, 2007 and June 22, 2007, respectively. This Amendment has an effective date of May 1, 2009. 
 NOW, THERFORE, for and in consideration of the mutual covenants, conditions and undertakings set forth, the Parties agree to amend the Agreement as follows: 

 

	 	1.	In addition to the funding described in Section 3.1 of the Agreement (which aggregate amount has already been paid by Sponsor to University), Sponsor shall provide
to University aggregate funding up to $[***] (the “Additional Funding”) with respect to the 4-month period of May, June, July, and August of 2009 (i.e., $[***] per month). Such Additional Funding shall be allocated and applied by
University (a) to carry out the Research under the Agreement, and (b) as outlined in the budget in Appendix A. 

  

	 	2.	University acknowledges that Sponsor has already paid University $[***] of the Additional Funding. Sponsor shall pay University the remaining balance of the Additional
Funding according to the following schedule: (a) Sponsor shall pay University $[***] following signature of this Amendment by both parties; and (b) Sponsor shall pay University the final $[***] on or before August 31, 2009.

  

	 	3.	University will provide Sponsor, on a timely basis, with information reasonably requested by Sponsor with respect to University’s actual allocation and application
of Additional Funding paid by Sponsor. 

 All other terms and conditions of the Agreement shall remain in full
force and effect and shall be unaffected by this Third Amendment to the Research Agreement. 
 IN WITNESS WHEREOF, the parties
have caused this Agreement to be executed by their duly authorized representatives effective as of the day and year first written above. 
  

									
	SURGIVISION, INC	 		 	UNIVERSITY OF UTAH
	    “Sponsor”	 		 	    “University”
					
	By:	 	 	 		 	By:	 	 
	Name:	 	Kim Jenkins	 		 	Name:	 	Brent K. Brown
	Title:	 	CEO	 		 	Title:	 	Director, Office of Sponsored

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 Appendix A 
 May-August 2009 Amended Budget for 
 SurgiVision/Siemens EP/MRI Collaboration
Project 
 [***] 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 2 

 FOURTH AMENDMENT TO THE RESEARCH AGREEMENT 

BY AND BETWEEN 
 SURGIVISION, INC. 
 AND 

THE UNIVERSITY OF UTAH 
 This is the Fourth Amendment to the Research Agreement (as previously amended, and as further amended by this Fourth Amendment, the “Research Agreement”), by and between SurgiVision,
Inc., a Delaware corporation having a place of business at One Commerce Square, Suite 2550, Memphis, TN 38103 (“Sponsor”), and the University of Utah, a body politic and corporate of the State of Utah with a place of business at 75
South 2000 East, Rm. 211, RAB, Salt Lake City, UT 84112 (“University”), executed by the Parties on July 2, 2007 and June 22, 2007, respectively. This Fourth Amendment is executed as of February 25, 2010, with an
effective date of September 1, 2009. 
 NOW, THERFORE, for and in consideration of the mutual covenants, conditions and
undertakings set forth, the parties agree to amend the Research Agreement as follows: 
 1. Defined Terms. Capitalized
terms used but not defined in this Fourth Amendment shall have the meanings ascribed to such terms in the Research Agreement. 

2. Extended Scope of Work. The term of the Research Agreement is extended through December 31, 2010. For the twelve
(12) month period commencing January 1, 2010 and ending December 31, 2010, University agrees to perform research activities described in or contemplated by the Scope of Work attached hereto as Exhibit A (the “SOW”)
for Sponsor’s exclusive benefit and to cooperate with Sponsor to facilitate a timely and successful completion of such research activities. For purposes of the Research Agreement, the term “Research” shall hereinafter include, without
limitation, research activities described in or contemplated by the SOW. University shall provide Sponsor the deliverables set forth in the SOW, on or before the dates set forth in the SOW. 

3. Additional SVI Support for Research. 
 (a) With respect to the four (4) month period commencing September 1, 2009 and ending December 31, 2009, Sponsor shall provide to University aggregate funding in the amount of [***], which
Sponsor shall pay in a single installment within thirty (30) days following the execution date of this Fourth Amendment. Such funding shall be allocated and applied by University (i) to carry out the Research for Sponsor’s exclusive
benefit, and (ii) to pay documented, reasonable and actual expenses in connection therewith. 
 (b) Provided
the Research Agreement is not earlier terminated, with respect to the twelve (12) month period commencing January 1, 2010 and ending December 31, 2010, Sponsor shall provide to University aggregate funding in an amount up to [***]
(the “Additional Funding”). The Additional Funding shall be allocated and applied by University (i) to carry out research activities described in or contemplated by the SOW for Sponsor’s exclusive benefit, and (ii) to
pay documented, reasonable and actual expenses in connection therewith, substantially in accordance with the itemized budget attached hereto as Exhibit B. Subject to the ultimate and penultimate sentences of this paragraph, and provided the Research
Agreement is 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 
not earlier terminated, Sponsor shall pay to University the Additional Funding in four (4) payments according to the following schedule: (A) the first payment, in an amount no more than [***]
will be due and payable as of April 15, 2010; (B) the second payment, in an amount no more than [***] will be due and payable as of July 15, 2010; (C) the third payment, in an amount no more than [***] will be due and payable as of October 15, 2010;
and (D) the fourth payment, in an amount no more than [***] will be due and payable as of January 15, 2011. Notwithstanding the foregoing to the contrary, Sponsor’s obligation to make each payment of the Additional Funding is contingent upon
University’s compliance with the Research Agreement, including, but in no way limited to, the SOW. Sponsor reserves the right to suspend or withhold any payment of funds if University fails to comply strictly with the terms and conditions of
the Research Agreement (which, for the avoidance of any doubt, includes this Fourth Amendment), including, but in no way limited to, the failure by University to achieve the milestones, and/or the failure by University to provide Sponsor the
milestone deliverables, as set forth in the SOW. 
 (c) University shall continue to account for the funding
provided by Sponsor separately in University’s books and records, provided all such funding may be accounted for in a single University project account. A systematic accounting record shall be kept by University of the receipt and disbursement
of funds. University shall retain original substantiating documents related to specific expenditures and make these records available for Sponsor’s review upon request. University shall be responsible for maintaining adequate financial records
of the research program. Sponsor, or a designated representative, reserves the right, upon reasonable written notice, to audit University’s books and records relating to the expenditure of the Additional Funding. 

(d) University shall provide Sponsor, on a timely basis as reasonably requested by Sponsor, with written reports that
describe in reasonable detail University’s actual allocation and application of funding provided by Sponsor (e.g., salaries, supplies, etc.). 
 4. Amendment to Section 4 of the Research Agreement (Technical Supervision). Section 4 of the Research Agreement (Technical Supervision) is hereby amended by adding the following at the
end of such section: 
 “In the event Dr. Nassir Marrouche leaves University or otherwise withdraws from his role in
the performance of the Research, Sponsor may, in its sole discretion, terminate this Agreement or consent to University’s designation of a replacement or substitute.” 

5. Amendment to Section 5 of the Research Agreement (Reporting Requirements). Section 5 of the Research Agreement
(Reporting Requirements) is hereby amended by deleting the first sentence thereof in its entirety and substituting the following therefore: 
 “University shall provide periodic written reports to Sponsor as requested by Sponsor, which reports shall set forth in reasonable detail the status of the Research and the progress in the
performance of the Research to achieve any applicable objectives and/or milestones.” 
 6. Amendment to Section 7.1
of the Research Agreement (Publication). Section 7.1 of the Research Agreement (Publication) is hereby amended by deleting the second paragraph thereof in its entirety and substituting the following therefore: 

“Notwithstanding the foregoing, to protect the confidentiality of Confidential Information (as defined below) and/or the
patentability of inventions and improvements conceived or reduced to practice in the performance of the Research, University agrees (for itself and all of its personnel) to provide to Sponsor, for Sponsor’s review and comment, any proposed
publications or presentations which will disclose any findings, data or results of the research conducted in connection with this Agreement as soon as 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 2 

 
possible, but in any event at least thirty (30) days prior to submission of a manuscript or abstract for publication or to the date of the presentation. If Sponsor reasonably determines that
the proposed publication or presentation contains patentable subject matter which requires protection, or discloses any Confidential Information, University agrees (for itself and all of its personnel) (i) to delay publication or presentation
for a period of time, not to exceed sixty (60) days, for the purpose of filing one or more patent applications and/or (ii) to delete any Confidential Information therefrom, other than results created by the University and included in a
publication by a University student conducting research under this Agreement where such publication is required for the student’s academic advancement. If no written response is received from Sponsor within Sponsor’s review period, the
publication or presentation may proceed without delay. In the event University defaults in the performance of its duties and obligation under this paragraph, Sponsor shall have the right (but not the obligation) to terminate this Agreement
immediately upon written notice to University.” 
 7. Amendment to Section 7.2 of the Research Agreement
(Confidentiality). Section 7.2 of the Research Agreement (Confidentiality) is hereby amended by deleting such section in its entirety and substituting the following therefore (provided these changes shall not apply retroactively from the
date of execution of this Amendment): 
 “7.2 Confidentiality. 

(a) During the term of this Agreement, (i) Sponsor may provide University with confidential information for use by
University personnel in carrying out the research activities under this Agreement and (ii) in the course of carrying out the research activities under this Agreement, University personnel may develop confidential information for the Company
(such information described in clauses (i) and (ii), the “Confidential Information”). Subject to the provisions of paragraph (b) below, University agrees (for itself and for all University personnel who will be using or
developing Confidential Information): 
 (1) to hold Confidential Information in strict confidence and not to
disclose Confidential Information to anyone other than University personnel working on research activities under this Agreement who have a need to know this information and who are obligated to comply with restrictions contained herein, except as
expressly provided in clause (ii) of the second paragraph of Section 7.1; 
 (2) to refrain from copying,
distributing, disclosing, or summarizing Confidential Information, except to University personnel identified in clause (i) above, or except as expressly provided in clause (ii) of the second paragraph of Section 7.1; 

(3) to treat Confidential Information with at least the same degree of care that University uses to protect the
confidentiality of its own most commercially sensitive information; 
 (4) to advise all University personnel to
whom Confidential Information is disclosed that Confidential Information is highly confidential and subject to stringent conditions of confidentiality, and that Confidential Information may not be disclosed to third parties, posted in whole or part
on the Internet, disclosed in publications or presentations, or otherwise handled or used in contravention of the terms of this Agreement; 
 (5) to use Confidential Information only in connection with Research performed under this Agreement, and to cease use of Confidential Information upon any termination of this Agreement (for whatever
reason); and 
 (6) to return Confidential Information to Sponsor upon termination of this Agreement (for
whatever reason), and to retain only one copy (which includes any copy stored in computer memory) provided that University may retain one copy (which includes any copy stored in computer memory) solely for archival purposes in order to determine
University’s obligations hereunder. 

  
 3 

 The foregoing restrictions contained in this Section 7.2 shall not apply to any
information that (i) is already in the public domain or becomes available to the public through no breach of this Agreement; (ii) was lawfully in the possession of University prior to receipt from Sponsor, without an obligation of
confidentiality; (iii) is received by University independently from a third party free to lawfully disclose such information to University; or (iv) is subsequently independently developed by University, outside the scope of the research
activities under this Agreement and without use of the Confidential Information, as evidenced by University’s written records. Furthermore, if University is ordered to disclose any Confidential Information by a court or other governmental
entity having jurisdiction, University may disclose such Confidential Information, provided that University (A) gives Sponsor prompt written notice of the order so Sponsor can seek a protective order or similar relief and (B) reasonably
cooperates with Sponsor in protecting the confidential or proprietary nature of the Confidential Information required to be so disclosed. Except for the limited rights of use granted herein, nothing in this Agreement gives University or University
personnel any rights, title, license or interest whatsoever in any Confidential Information. All ownership and other rights therein are vested in and shall remain with Sponsor. 

(b) Sponsor acknowledges that University is a governmental entity subject to the Government Records Access and Management
Act, Utah Code §§ 63G-2-101 to -901, as amended, and Utah Code §§ 53B-16-301 through 53B-16-305, as amended (“Records Statutes”). As such, University’s confidentiality obligations under this Agreement shall be
subject in all respects to University’s compliance with Records Statutes. Pursuant to §§ 53B-16-304 and 63G-2-309 of the Utah Code, as amended, Sponsor hereby claims that the records it provides to University in connection with this
Agreement are confidential and protected against disclosure under Utah Code §§ 53B-16-302 and 63G-2-305, as amended, as such records relate to Sponsor’s proprietary research and development efforts. Accordingly, in the event that
University receives a request, pursuant to the Records Statutes, for records related to this Agreement, University shall be foreclosed, absent a court order or consent or acquiescence from Sponsor, from making the requested
disclosure. Notwithstanding the foregoing, in the event that University receives a request for records related to this Agreement, University shall, if deemed necessary by University’s legal counsel, release a general description of the
research conducted under this Agreement, excluding proprietary or competitive information, consistent with the provisions of §§ 53B-16-302 of the Utah Code, as amended. University shall promptly notify Sponsor in writing of any request it
receives for records related to this Agreement. 
 8. Amendment to Section 10.3 of the Research Agreement
(Ownership). Section 10.3 of the Research Agreement (Ownership) is hereby amended by deleting such section in its entirety and substituting the following therefore: 

“10.3 Ownership. The University shall own all right, title and interest in all inventions and improvements
conceived or reduced to practice, and all copyrightable materials created, solely by University or University personnel in the performance of the Research (hereinafter collectively “University Invention”). Sponsor shall own all right,
title and interest in all inventions and improvements conceived or reduced to practice, and all copyrightable materials created, by Sponsor, Sponsor personnel and/or consultants thereof in the performance of the Research (hereinafter collectively
“Sponsor Invention”). The University and Sponsor will jointly own all right, title and interest in all inventions and improvements jointly conceived or reduced to practice, and all copyrightable materials created, by personnel at the
University and at Sponsor in the performance of the Research (hereinafter collectively “Joint Invention”). Inventorship shall be determined in accordance with U.S. Patent Law.” 

  
 4 

 9. Amendment to Section 12 of the Research Agreement (Termination).
Section 12 of the Research Agreement (Termination) is hereby amended by deleting such section in its entirety and substituting the following therefore: 
 “12. Termination. 
 12.1 Term. Unless earlier
terminated as provided below, the term of this Agreement shall continue through December 31, 2010. 
 12.2
Default. If either Sponsor or University materially defaults in the performance of any duty or obligation imposed upon it by this Agreement and such default continues for thirty (30) days after written notice thereof has been given to
the defaulting party by the other party, such other party may (but need not) give notice of the immediate termination of this Agreement. Notwithstanding the foregoing to the contrary, Sponsor may terminate this Agreement immediately upon notice to
University in the event University defaults in the performance of its duties and obligations under Section 7.1 or Section 7.2 of this Agreement. 
 12.3 Primary Researcher. Sponsor shall have the right (but not the obligation) to terminate this Agreement upon written notice to University under the circumstances set forth in Section 4
hereof. 
 12.4 Return of Confidential Information. Upon termination of this Agreement for any reason,
University must promptly return to Sponsor all of Sponsor’s Confidential Information then in the possession or under the control of University and/or any of its personnel, provided that University may retain one copy (which includes any copy
stored in computer memory) of the Confidential Information for archival purposes in order to determine University’s obligations hereunder. 
 10. Amendment to Section 14 of the Research Agreement (Miscellaneous). Section 14 of the Research Agreement (Miscellaneous) is hereby amended by adding the following Section 14.10:

 “14.10 Research Involving Animals. With respect to any research activities covered by this
Agreement involving animal subjects, University agrees to comply with all applicable laws, rules and regulations of any governmental authority, agency or entity having jurisdiction over the research (including, but not limited to, the 1966 Federal
Animal Welfare Act and the 1985 Improved Standards of Laboratory Animals Acts.) This compliance includes, but is not limited to, the need for review and approval of University’s animal research/procedures for animal care by the appropriate
local Institutional Animal Care and Use Committee (IACUC). If such approval is required, University must provide a copy of this approval to Sponsor.” 
 11. Amendment to Section 14 of the Research Agreement (Miscellaneous). Section 14 of the Research Agreement (Miscellaneous) is hereby amended by adding the following Section 14.11:

 “14.11 Prohibition on Practice of Medicine. Notwithstanding anything to the contrary contained in
this Agreement, the parties acknowledge that Sponsor is not authorized or qualified to engage in any activity which may be construed or deemed to constitute the practice of medicine. Accordingly, University shall retain the authority to direct all
medical decisions regarding the care and treatment of its 

  
 5 

 
patients and shall assume full responsibility for any clinical decisions made as a result of data, directly or indirectly, generated during the research activities conducted. Sponsor shall
neither exercise control over nor interfere with the physician-patient relationship. To the extent any act or service required of Sponsor under this Agreement should be construed or deemed by a governmental authority, agency or court to constitute
the practice of medicine, the performance of said act or service by Sponsor shall be deemed waived and forever unenforceable.” 
 12. Amendment to Section 14 of the Research Agreement (Miscellaneous). Section 14 of the Research Agreement (Miscellaneous) is hereby amended by adding the following Section 14.12:

 “14.12 Anti-Kickback Statute. In compliance with the federal Medicare/Medicaid Anti-Kickback
Statute, each party represents that the funding to University has not been determined with regard to any implicit or explicit agreement to provide favorable procurement decisions with regard to Sponsor’s products or product candidates, and have
not been given in exchange for such decisions. Each party further represents that such compensation has not been determined with regard to the value or volume of any business generated between the parties and that such compensation is consistent
with fair market value in arm’s length transactions. The compensation provided hereunder is directly related to the costs of carrying out research, and includes no incentive payment to any individual for identifying or recruiting human
subjects. This Agreement is not intended to, and does not, induce the referral of patients or to induce purchase of any items or services reimbursed by any federal or state health care program.” 

13. Amendment to Section 14 of the Research Agreement (Miscellaneous). Section 14 of the Research Agreement
(Miscellaneous) is hereby amended by adding the following Section 14.13: 
 “14.13 Survival. The
provisions of Section 7 (Publication and Confidentiality), Section 8 (Indemnification), Section 10 (Patents and Inventions) Section 12.4 (Return of Confidential Information), and Section 14 (Miscellaneous) of this Agreement
(including subsections) will survive any termination of this Agreement.” 
 14. Change of Address. Notices and other
communications given to Sponsor under Section 14.4 (Notices) of the Research Agreement shall be sent or delivered to the addresses set forth below, or to such other address(es) as Sponsor shall designate by written notice given to University:

  

			
	Technical	  	Contractual
		
	Pete Piferi	  	Kimble Jenkins
	COO	  	CEO
	5 Musik	  	One Commerce Square, Ste. 2550
	Irvine, CA 92618	  	Memphis, TN 38103

 In each case with a courtesy copy to: 
 Oscar Thomas 
 VP, Business Affairs 
 One Commerce Square, Ste. 2550 
 Memphis, TN 38103 

  
 6 

 15. Exhibits. The Exhibits attached to this Fourth Amendment are hereby incorporated
into and made a part of this Fourth Amendment. 
 16. Ratification and Confirmation of Research Agreement. The parties
each acknowledge and agree that the Research Agreement is in full force and effect and has been in full force and effect at all times since its execution. The terms and provisions of the Research Agreement, as modified by the terms of this Fourth
Amendment, are hereby ratified and confirmed in all respects. 
 [The next page is the signature page] 

***** 

  
 7 

 IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by their duly
authorized representatives. 
  

									
	SURGIVISION, INC.	 		 	UNIVERSITY OF UTAH
	    “Sponsor”	 		 	    “University”
					
	By:	 	/s/ Kimble L. Jenkins	 		 	By:	 	/s/ Brent K. Brown
	Name:	 	Kimble L. Jenkins	 		 	Name:	 	Brent K. Brown
	Title:	 	CEO	 		 	Title:	 	Director, Office of Sponsored Projects

  
 8 

 Exhibit A 
 Scope of Work 
 [***] 

 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 9 

 Exhibit B 
 Budget 
 [See Attached] 

  
 16 

 [***] 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 17 

 FIFTH AMENDMENT TO THE RESEARCH AGREEMENT 

BY AND BETWEEN 
 SURGIVISION, INC. 
 AND 

THE UNIVERSITY OF UTAH 
 UNIVERSITY OF UTAH REFERENCE NUMBER 10004541 AMENDMENT 5 
 This is the
Fifth Amendment to the Research Agreement (as previously amended, and as further amended by this Fifth Amendment, the “Research Agreement”), by and between SurgiVision, Inc., a Delaware corporation having a place of business at One
Commerce Square, Suite 2550, Memphis, TN 38103 (“Sponsor”), and the University of Utah, a body politic and corporate of the State of Utah with a place of business at 75 South 2000 East, Rm. 211, RAB, Salt Lake City, UT 84112
(“University”), executed by the Parties on July 2, 2007 and June 22, 2007, respectively. This Fourth Amendment is executed as of December 31, 2010, with an effective date of January 1, 2011. 

NOW, THERFORE, for and in consideration of the mutual covenants, conditions and undertakings set forth, the parties agree to amend the
Research Agreement as follows: 
 1. Defined Terms. Capitalized terms used but not defined in this Fifth Amendment shall
have the meanings ascribed to such terms in the Research Agreement. 
 2. Extended Scope of Work. The term of the
Research Agreement is extended through December 31, 2011. For the twelve (12) month period commencing January 1, 2011 and ending December 31, 2011, University agrees to perform research activities described in or contemplated by
the Scope of Work attached hereto as Exhibit A (the “SOW”) for Sponsor’s exclusive benefit and to cooperate with Sponsor to facilitate a timely and successful completion of such research activities. For purposes of the Research
Agreement, the term “Research” shall hereinafter include, without limitation, research activities described in or contemplated by the SOW. University shall provide Sponsor the deliverables set forth in the SOW, on or before the dates set
forth in the SOW. 
 3. Additional SVI Support for Research 

 

	 	(a)	 Provided the Research Agreement is not earlier terminated, with respect to the twelve (12) month period commencing January 1, 2011 and ending
December 31, 2011, Sponsor shall provide to University aggregate funding in an amount up to [***] (the “Additional Funding”). Carry over of previously awarded funding is approved from the previous project periods to the new
project period. The Additional Funding shall be allocated and applied by University (i) to carry out research activities described in or contemplated by the SOW for Sponsor’s exclusive benefit, and (ii) to pay documented, reasonable
and actual expenses in connection therewith, substantially in accordance with the itemized budget attached hereto as Exhibit B. Subject to the ultimate and penultimate sentences of this paragraph, and provided the Research Agreement is not earlier
terminated, Sponsor shall pay to University the Additional Funding in four (4) payments according to 

  

	[***]  	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

	 	
the following schedule: (A) the first payment, in the amount of [***], will be due and payable as of April 15, 2011; (B) the second payment, in the amount of [***], will be due and
payable as of July 15, 2011; (C) the third payment, in the amount of [***], will be due and payable as of October 15, 2011; and (D) the fourth payment, in the amount of [***], will be due and payable as of January 15, 2012.
Notwithstanding the foregoing to the contrary, Sponsor’s obligation to make each payment of the Additional Funding is contingent upon University’s compliance with the Research Agreement, including, but in no way limited to, the SOW.
Sponsor reserves the right to suspend or withhold any payment of funds if University fails to comply strictly with the terms and conditions of the Research Agreement (which, for the avoidance of any doubt, includes this Fifth Amendment), including,
but in no way limited to, the failure by University to achieve the milestones, and/or the failure by University to provide Sponsor the milestone deliverables, as set forth in the SOW. 

 

	 	(b)	University shall continue to account for the funding provided by Sponsor separately in University’s books and records, provided all such funding may be accounted
for in a single University project account. A systematic accounting record shall be kept by University of the receipt and disbursement of funds. University shall retain original substantiating documents related to specific expenditures and make
these records available for Sponsor’s review upon request. University shall be responsible for maintaining adequate financial records of the research program. Sponsor, or a designated representative, reserves the right, upon reasonable written
notice, to audit University’s books and records relating to the expenditure of the Additional Funding. 

  

	 	(c)	University shall provide Sponsor, on a timely basis as reasonably requested by Sponsor, with written reports that describe in reasonable detail University’s actual
allocation and application of funding provided by Sponsor (e.g., salaries, supplies, etc.). 

 4. Amendment to
Section 12 of the Research Agreement (Termination). Section 12.1 of the Research Agreement (Term) is hereby amended by deleting such section in nits entirety and substituting the following therefor: 

“12.1 Term. Unless earlier terminated as provided below, the term of this Agreement shall continue through
December 31, 2011.” 
 5. Exhibits. The Exhibits attached to this Fifth Amendment are hereby incorporated into
and made a part of this Fifth Amendment. 
 6. Ratification and Confirmation of Research Agreement. The parties each
acknowledge and agree that the Research Agreement is in full force and effect and has been in full force and effect at all times since its execution. The terms and provisions of the Research Agreement, as modified by the terms of this Fifth
Amendment, are hereby ratified and confirmed in all respects. 

  

	[***]  	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by their duly
authorized representatives. 
  

									
	SURGIVISION, INC.	 		 	UNIVERSITY OF UTAH
	“Sponsor”	 		 	“University”
					
	By:	 	/s/ Kimble Jenkins	 		 	By:	 	/s/ Brent Brown
	Name:	 	Kimble L. Jenkins	 		 	Name:	 	Brent K. Brown
	Title:	 	CEO	 		 	Title:	 	Director, Office of Sponsored

  

 Exhibit A 
 Scope of Work 
 [***] 

  

	[***]  	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 Exhibit B 
 Budget 
 [See Attached] 

  

 [***] 

  

	[***]  	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 SIXTH AMENDMENT TO THE RESEARCH AGREEMENT 

BY AND BETWEEN 
 MRI INTERVENTIONS, INC 
 (FORMERLY SURGIVISION, INC.) 

AND 
 THE
UNIVERSITY OF UTAH 
 UNIVERSITY OF UTAH REFERENCE NUMBER 10004541 AMENDMENT 6 

This is the Sixth Amendment to the Research Agreement (as previously amended, and as further amended by this Sixth Amendment, the
“Research Agreement”), by and between MRI Interventions, Inc. (formerly SurgiVision, Inc.), a Delaware corporation having a place of business at One Commerce Square, Suite 2550, Memphis, TN 38103 (“Sponsor”), and
the University of Utah, a body politic and corporate of the State of Utah with a place of business at 75 South 2000 East, Rm. 211, RAB, Salt Lake City, UT 84112 (“University”), executed by the Parties on July 2, 2007 and June 22,
2007, respectively. This Sixth Amendment is executed as of 28 November 2011, with an effective date of 28 November 2011. 

Whereas all the terms and conditions agreed upon in the Research Agreement shall remain in full force and effect, and enforceable in
accordance with its terms, with the exception of the amendments provided herein. 
 NOW, THERFORE, for and in consideration of
the mutual covenants, conditions and undertakings set forth, the parties agree to amend the Research Agreement as follows: 

1.        Defined Terms. Capitalized terms used but not defined in this Sixth Amendment
shall have the meanings ascribed to such terms in the Research Agreement. 

2.        Extended Term. The term of the Research Agreement is extended through 31 March
2012. 
 IN WITNESS WHEREOF, the parties have caused this Sixth Amendment to be executed by their duly authorized
representatives. 
  

													
		 	 SURGIVISION, INC.
           “Sponsor”
	 		 	 UNIVERSITY OF UTAH
           “University”
	 	
							
		 	By:	 	   /s/ Kimble L. Jenkins
	 		 	By:	 	   /s/ Todd B. Nilsen
	 	
		 	Name: Kimble L. Jenkins	 	Name: Todd B. Nilsen, J.D.	 	
		 	Title: CEO	 	Title: Associate Director	 	
		 		 		 		 	         Sponsored Projects

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}]]